Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib was administered as 160 mg twice daily (n = 14), 320...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Tam, Constantine S., Opat, Stephen, Simpson, David, Cull, Gavin, Munoz, Javier, Phillips, Tycel J., Kim, Won Seog, Rule, Simon, Atwal, Siminder Kaur, Wei, Rachel, Novotny, William, Huang, Jane, Wang, Michael, Trotman, Judith
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2021
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8270663/
https://ncbi.nlm.nih.gov/pubmed/34152395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020004074
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak